Biological Information
Background Information:
Prostanoid receptors belong to the superfamily of G protein-coupled seven transmembrane proteins. G-protein-coupled receptors constitute one of the major signal transduction systems in eukaryotic cells. Coding sequences for these receptors, in those regions believed to contribute to the agonist-antagonist binding site, are strongly conserved across mammalian species. Prostanoid FP is a member of the prostaglandin series which are derived de novo from arachidonic acid and constitute the most abundant of the naturally occurring prostanoids. FP receptors are considered to be involved in smooth muscle contraction such as the uterus, vasculature, gastrointestinal tract, etc.
No. of Assays on Panel:
2
Assays on Panel:
Family
GPCR
Name
FP Human Prostanoid GPCR Cell Based Agonist Calcium Flux LeadHunter Assay - FR
Item
2011
Protein
FP
Organism
Human
Assay Sub Type
Cell Based
Family
GPCR
Name
FP Human Prostanoid GPCR Cell Based Antagonist Calcium Flux LeadHunter Assay - FR
Item
2013
Protein
FP
Organism
Human
Assay Sub Type
Cell Based
Family:
GPCR
Sub Family:
Prostanoid
Class:
Class A
Protein Name:
FP
Uniprot Number:
P43088
Protein Aliases:
PGF2-alpha receptor|Prostanoid FP receptor
Gene Name:
PTGFR
Gene ID:
5737
Gene Aliases:
FP
Organism:
Human
Cell Type:
HEK293
Assay Information
Assay Type:
Functional
Assay Sub Type:
Cell Based
Functional Mode:
Agonist & Antagonist
Detection Method:
Fluorimetry
Measured Response:
Fluorescence
Testing Information
Incubation:
RT
Control Activator:
PGF2alpha (5 nM)
Test Concentration / Dose:
Eurofins will provide IC/EC50 calculation if 5 or more concentrations are selected.
Test Sample Requirements:
Minimum for 1) Screen: 70 µL of 10 mM stock -OR- 1 mg (pre-weighed) for 10µM finµL testing. 2) Dose Response: 90 µL of 10 mM stock -OR- 1 mg (pre-weighed) for a top concentration at 10 µM.
Minimum Order Quantity:
16
Turnaround Time
Standard:
15 Business Days
Clinical Relevance
Therapeutic Area:
CNS/Addiction/Pain
Adverse / Beneficial Action:
FP receptor agonism may be useful in the treatment of ocular hypertension but may also be involved in untoward effects such as ocular hyperemia, cystoid macular edema, irishyperpigmentation or melanogenesis, excessive bone deposition, andpremature labor.
Additional Information
Brand:
LeadHunter
Testing Location:
France - Celle L'Evescault
RELATED SOLUTIONS